Back to top
more

IntraCellular Therapies (ITCI)

(Delayed Data from NSDQ)

$86.17 USD

86.17
713,064

-0.37 (-0.43%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $86.22 +0.05 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -38.89% and 2.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.

RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease

Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 11.11% and 1.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates

Beyond Air (XAIR) delivered earnings and revenue surprises of 6.90% and 5.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe

Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?

Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.